Interview: Omer Saka – Director Health Economy & Market Access…
Deloitte is certainly renowned for its strong network of international expertise in the field of life sciences having teams in all of the crucial markets able to cater to their…
Address: Haasrode Researchpark 1724
Romeinse straat 12 bus 2
3001 Leuven
Belgium
Tel: +32 (0) 16 39 60 60
TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and a strong clinical stage pipeline of adult stem cell programs. The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being launched across Europe. TiGenix’s adipose derived allogeneic stem cell platform has been extensively validated. The company has initiated a Phase III clinical trial to treat complex perianal fistulas in patients with Crohn’s disease, has a Phase IIa trial in rheumatoid arthritis ongoing, and has successfully concluded a Phase I trial to investigate intra-lymphatic administration in autoimmune disorders. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
ChondroCelect® for cartilage regeneration in the knee is an implantation suspension of characterised viable autologous (from the patient her- or himself) cartilage cells. The product is administered to patients in an autologous chondrocyte implantation procedure known as Characterised Chondrocyte Implantation (CCI), a surgical procedure to treat cartilage defects, in conjunction with debridement (preparation of the defect bed), a physical seal of the lesion (placement of a biological membrane, preferentially a collagen membrane) and rehabilitation.
ChondroCelect is the first cell-based product to successfully complete the entire development track from research to clinical development to approval by the European Medicines Agency as an Advanced Medicinal Therapy Product in October, 2009. ChondroCelect is commercially available in Belgium, the Netherlands, Luxemburg, Germany, the United Kingdom, Finland, and Spain.
Moreover, TiGenix uniquely combines early stage revenues from its ChondroCelect sales with the mid- to long-term commercial potential from its expanded adipose stem cell pipeline.
Deloitte is certainly renowned for its strong network of international expertise in the field of life sciences having teams in all of the crucial markets able to cater to their…
Deloitte is certainly renowned for its strong network of international expertise in the field of life sciences having teams in all of the crucial markets able to cater to their…
Donald Niesten and Omer Saka discuss the current dynamics of the healthcare and pharmaceutical sectors in Belgium, the challenges of entering the market and the issue of effective communication…
Mr Pasini, before becoming site director of the Verviers plant you were acting as the Head of Investor Relations for Lonza. Can you provide us with an overview of your…
Having worked in internal clinical research for Eli Lilly for 14 years, from 1993 – 2007, what has this experience taught you about what pharmaceutical companies need in an outsourcing…
Deloitte is certainly renowned for its strong network of international expertise in the field of life sciences having teams in all of the crucial markets able to cater to their…
This August marks your sixth year at the helm of the Belgian affiliate of Ferring, what would you say best explains your loyalty to the company? One element that appeals…
UCB was founded in 1928 by Mr Emmanuel Janssen in Belgium, what spirit would you say its founder left behind and what core values unique to the company were you…
Since 1969, Eli Lilly & Company has been investing in Belgium. Can you give our readers a brief overview of the company’s history here and highlight some of your most…
The managing director of Brussels Invest & Export discusses Belgium’s unique attractiveness when it comes to the life sciences, and which countries and companies are interested in investing in the…
Could you tell our readers who are not familiar with the Biopark with an introduction of the Biopark and its institutes? The BioPark of Charleroi Brussels South is a campus…
The generics market in Belgium doesn’t seem to be at the level it deserves to be. Considering that Mylan controls about 14% of the local generics market share, how would…
See our Cookie Privacy Policy Here
